Last updated: September 22, 2026
Letermovir, marketed as Prevymis by Merck & Co., is a small-molecule antiviral used to prevent cytomegalovirus, or CMV, infection in high-risk transplant patients. Its commercial trajectory has strengthened since its 2017 launch, driven by adoption in allogeneic hematopoietic stem-cell transplant patients and the 2023 expansion into high-risk kidney transplant recipients.
Merck’s Prevymis sales increased from approximately $824 million in 2022 to about $1.0 billion in 2023 and continued growing in 2024. The product has a differentiated prophylaxis profile, limited direct competition and a long patent runway relative to its original regulatory exclusivity. The principal commercial risks are reimbursement pressure, transplant-volume sensitivity, drug-interaction management and eventual generic entry after the expiry of later-issued formulation and use patents.
What is letermovir used for?
Letermovir is a CMV DNA terminase complex inhibitor. It blocks viral DNA processing and packaging through a mechanism distinct from ganciclovir, valganciclovir, foscarnet and cidofovir.
The product is administered as an oral tablet, oral solution or intravenous formulation. Its approved uses are:
| Market |
Patient population |
Treatment duration |
| Allogeneic HSCT |
Adult and pediatric patients at risk of CMV reactivation or disease who are CMV-seropositive before transplant |
Through approximately 100 days after transplant, with selected patients receiving longer prophylaxis |
| Kidney transplant |
Adult kidney transplant recipients at high risk of CMV disease, generally donor-positive/recipient-negative |
Up to 200 days after transplant |
The FDA approved Prevymis in November 2017 for CMV prophylaxis in adult CMV-seropositive recipients of allogeneic HSCT. In June 2023, the agency approved it for prevention of CMV disease in high-risk adult kidney transplant recipients through 200 days after transplantation (FDA, 2017, 2023).
How large is the letermovir market?
The addressable market is concentrated but commercially attractive. Letermovir is used in specialized transplant settings where CMV disease can cause hospitalization, graft complications, mortality and increased healthcare costs.
Hematopoietic stem-cell transplant market
The allogeneic HSCT market provides the original commercial base. Use is strongest in patients with substantial CMV reactivation risk and in centers that have adopted routine prophylaxis rather than relying exclusively on preemptive viral-load monitoring.
Commercial demand is influenced by:
- Annual allogeneic HSCT volume.
- The proportion of transplant recipients who are CMV-seropositive.
- Institutional prophylaxis protocols.
- Duration of prophylaxis.
- Adoption in pediatric and higher-risk transplant populations.
- Comparative use against preemptive valganciclovir or ganciclovir-based strategies.
The pivotal randomized trial showed lower clinically significant CMV infection with letermovir than placebo in CMV-seropositive allogeneic HSCT recipients. The trial also demonstrated lower all-cause mortality by week 24, supporting hospital formulary adoption (Marty et al., 2017).
Kidney transplant market
The kidney indication materially increased the addressable population. Kidney transplantation is performed at a higher annual volume than allogeneic HSCT, although the eligible subgroup is narrower because the FDA indication focuses on CMV donor-positive/recipient-negative patients.
The kidney market has a longer treatment course than the original HSCT indication. Prophylaxis can continue for 200 days, compared with the standard 100-day post-HSCT period. That increases revenue per treated patient and gives Merck access to transplant centers that may not have used letermovir for HSCT.
A phase 3 trial found letermovir noninferior to valganciclovir for prevention of CMV disease in high-risk kidney transplant recipients. Letermovir was associated with less leukopenia or neutropenia, an important clinical and operational advantage in patients receiving immunosuppressive therapy (Limaye et al., 2023).
What is Merck’s financial trajectory for Prevymis?
Merck does not generally disclose Prevymis patient counts, average realized price or gross-to-net deductions separately. Reported sales show a clear upward trend.
| Fiscal year |
Approximate Prevymis sales |
Commercial interpretation |
| 2021 |
$0.7 billion |
Established HSCT adoption |
| 2022 |
$0.8 billion |
Continued transplant-center penetration |
| 2023 |
$1.0 billion |
Kidney-transplant approval and broader use |
| 2024 |
Approximately $1.0 billion or above |
Expansion of the kidney indication and durable HSCT demand |
Source: Merck annual reports and financial filings (Merck & Co., 2022, 2023, 2024).
The 2023 increase was strategically important because it demonstrated that Prevymis could continue growing after the initial HSCT launch. The kidney indication expands both patient volume and treatment duration. The commercial effect will depend on how rapidly transplant centers shift high-risk kidney patients from valganciclovir to letermovir and whether payers impose step therapy or prior authorization.
Prevymis remains a relatively small product within Merck’s portfolio, which is dominated by Keytruda, Gardasil and other large franchises. Its revenue is still material because it has a specialized market, premium positioning and limited direct competition.
What drugs compete with letermovir?
Letermovir competes primarily with older CMV prophylaxis and preemptive-treatment strategies, not with another identical mechanism.
| Product or strategy |
Role |
Main competitive issue |
| Valganciclovir |
CMV prophylaxis and treatment |
Lower cost and broad familiarity; myelosuppression is a major limitation |
| Ganciclovir |
Intravenous prophylaxis or treatment |
Bone-marrow toxicity and intravenous administration |
| Foscarnet |
Treatment of resistant or refractory CMV |
Nephrotoxicity and intravenous delivery |
| Cidofovir |
Rescue treatment |
Nephrotoxicity and limited routine use |
| Maribavir |
Treatment of refractory or resistant CMV |
Not a direct prophylaxis substitute in the principal approved use |
| CMV PCR surveillance with preemptive therapy |
Management strategy |
Avoids universal prophylaxis but requires monitoring and rapid intervention |
Letermovir’s strongest competitive advantage is reduced hematologic toxicity compared with valganciclovir. Its main disadvantages are price, drug-drug interactions and the need for careful selection in patients receiving calcineurin inhibitors, azole antifungals or other interacting medicines.
Maribavir is a relevant Merck-adjacent comparator because it is approved for refractory or resistant CMV infection after transplant. It is primarily a treatment product, while letermovir is primarily a prophylaxis product. The two products address different points in the CMV care pathway.
What FDA exclusivity does letermovir have?
Letermovir received several forms of regulatory protection, but FDA market exclusivity is separate from patent protection.
| Protection |
Relevant milestone |
Commercial effect |
| New chemical entity exclusivity |
2017 approval |
Blocked abbreviated new drug application approval for five years, subject to statutory exceptions |
| Orphan-drug exclusivity |
HSCT indication |
Provided seven years of exclusivity for the designated orphan use |
| Supplemental approval protection |
2023 kidney-transplant indication |
May provide three years of exclusivity for the new clinical investigation supporting the approval |
| Patent protection |
Multiple U.S. and international families |
Determines practical timing of generic launch after regulatory exclusivity |
The original five-year new chemical entity period and seven-year orphan period have expired or reached the end of their principal terms. The 2023 kidney-transplant approval added regulatory value but does not recreate full new chemical entity exclusivity for the entire product.
A generic company can seek approval for a nonprotected indication, subject to the scope of listed patents and applicable regulatory rules. The commercial significance of the 2023 approval therefore depends on which patents cover the product itself, the dosage forms, the dosing regimen and the transplant indication.
What patents protect Prevymis and letermovir?
Letermovir has a layered patent estate rather than a single protection date. The relevant categories include:
- Composition-of-matter patents covering letermovir and related antiviral compounds.
- Solid-state, salt, crystal-form or manufacturing patents.
- Pharmaceutical composition patents covering tablets, oral solutions or intravenous formulations.
- Method-of-use patents covering CMV prophylaxis in transplant patients.
- Dosing and treatment-duration patents associated with specific transplant populations.
The earliest core compound families originated from Merck’s discovery program and include international filings such as WO 2006/133822. Later U.S. patents and continuations extend protection for formulations, therapeutic uses and manufacturing aspects. Patent terms differ by jurisdiction and can be affected by patent-term adjustment, patent-term extension, terminal disclaimers and pediatric exclusivity.
The practical U.S. generic-entry date is therefore likely to be determined by the latest enforceable Orange Book-listed patent, not by the expiry of the original compound patent alone. Public patent databases commonly place certain core letermovir protection in the late 2020s or around 2030, while later formulation and method-of-use patents may extend into the 2030s. Exact entry timing depends on the patents listed by FDA, the claims challenged and the outcome of any Paragraph IV litigation.
The FDA Orange Book should be treated as the controlling commercial reference for listed patents, expiration dates and exclusivity status. Patent databases can contain expired, unlisted, cancelled or nonblocking family members and should not be used alone to set a launch date (FDA, 2025).
Are there Paragraph IV challenges to letermovir?
No major public Paragraph IV litigation has established an imminent U.S. generic launch for Prevymis in the public record covered by the cited sources.
A future ANDA filer could challenge:
- The validity of composition patents.
- The enforceability of formulation patents.
- The scope of method-of-use claims.
- Obviousness based on prior art involving CMV prophylaxis.
- Written-description or enablement issues for dosing and transplant-use claims.
A generic entrant could also pursue a section viii statement that omits a patented indication, depending on the Orange Book listing and the commercial importance of the remaining unprotected uses. That approach could permit an earlier launch for a narrower label if the product and formulation claims no longer block approval.
The absence of a disclosed settlement or court judgment does not eliminate future challenge risk. The primary commercial defense is the layered nature of the estate and the specialized clinical market, which raises the cost of switching protocols even after a generic product becomes technically available.
What is the biosimilar risk for letermovir?
There is no biosimilar risk because letermovir is a chemically synthesized small molecule, not a biologic. Future competition would proceed through the abbreviated new drug application pathway, not the biosimilar pathway.
This distinction matters commercially. Generic entrants can rely on pharmaceutical equivalence and bioequivalence rather than reproducing a complex biologic manufacturing process. The principal barriers are patent claims, formulation replication, regulatory requirements and transplant-center adoption.
What manufacturing and IP barriers affect generic entry?
Manufacturing complexity is meaningful but not equivalent to the barriers associated with biologics.
Potential barriers include:
- Reproducing the required solid-state form.
- Controlling impurity profiles for a complex antiviral molecule.
- Matching tablet dissolution and stability.
- Producing the oral solution with acceptable shelf life.
- Demonstrating bioequivalence across dosage forms.
- Managing intravenous formulation requirements.
- Avoiding process patents and formulation claims.
- Establishing reliable supply for a relatively specialized market.
The oral tablet is likely to be the first target for generic development because it is easier to distribute and more commercially scalable than the intravenous presentation. A generic that omits a protected kidney-transplant indication could still face a narrower commercial opportunity if the indication is economically important.
When could generic letermovir launch?
A generic launch before the mid-to-late 2020s appears unlikely to be the base case because the product’s principal commercial protection extends beyond its original NCE and orphan exclusivity. The more relevant launch window is tied to the latest enforceable Orange Book patents, which may push meaningful U.S. entry toward approximately 2030 or later.
Potential launch scenarios are:
| Scenario |
Timing |
Commercial result |
| Early settlement launch |
Before the last patent expiry |
Limited-volume or licensed entry |
| Section viii launch |
After unpatented indications become available |
Narrow label and limited share |
| First-filer launch after patent challenge |
Around the first blocking patent expiry |
Potential 180-day competitive advantage |
| Full-label generic launch |
After all relevant listed patents expire or are invalidated |
Rapid price erosion and formulary substitution |
The magnitude of price erosion will depend on the number of approved entrants. A single generic may preserve a meaningful price premium in transplant centers, while multiple entrants would create conventional small-molecule discounting.
How strong is the letermovir patent estate?
The patent estate is commercially strong but not unassailable.
Strengths include:
- A clinically validated composition with a distinct mechanism.
- Multiple dosage forms.
- A high-value prophylaxis indication.
- Later approval in kidney transplantation.
- Specialized prescribing and hospital-formulary barriers.
- Potentially overlapping composition, formulation and method-of-use protection.
Risks include:
- Expiry of original compound protection.
- Challenges to later patents as obvious or insufficiently supported.
- Difficulty enforcing method-of-use claims against a generic that uses a section viii label.
- Limited ability to prevent off-label prescribing after generic entry.
- Potential price pressure before complete estate expiry through authorized or at-risk entry.
What licensing deals affect letermovir?
Merck retains the commercial rights to Prevymis globally. No major third-party licensing transaction is central to the current Prevymis commercial model in the public sources cited here. The product’s economics are therefore driven primarily by Merck’s internal development, manufacturing, regulatory and commercial operations rather than royalty-sharing arrangements.
What is the commercial outlook for letermovir?
Prevymis is likely to remain a billion-dollar-class transplant product during the current decade if kidney-transplant adoption continues and HSCT utilization remains stable. Growth will come from treatment-duration expansion and protocol conversion rather than from broad primary-care prescribing.
The main upside drivers are:
- Greater use in high-risk kidney recipients.
- Longer prophylaxis duration.
- Pediatric and higher-risk transplant uptake.
- Reduced use of valganciclovir because of cytopenias.
- Continued guideline and institutional adoption.
- Premium pricing supported by reduced monitoring and toxicity.
The main downside risks are:
- Payer restrictions.
- Generic or authorized-generic entry.
- CMV surveillance strategies that reduce prophylaxis use.
- Drug-interaction concerns.
- Declining transplant volumes or changes in immunosuppressive regimens.
- Failure to demonstrate sufficient economic value over valganciclovir.
Key Takeaways
- Letermovir is Merck’s Prevymis, a CMV prophylaxis drug for transplant patients.
- Sales rose from approximately $824 million in 2022 to about $1.0 billion in 2023, with continued strength in 2024.
- The 2023 kidney-transplant approval expanded the addressable market and increased potential revenue per patient through a 200-day prophylaxis course.
- Valganciclovir is the main clinical and economic competitor.
- Letermovir has no biosimilar risk because it is a small molecule.
- The important protection now comes from layered patents covering composition, formulations, manufacturing and transplant-related uses.
- Generic entry is unlikely to be governed by the original five-year NCE period alone and may depend on patents extending into approximately 2030 or later.
- No major public Paragraph IV settlement or litigation outcome establishes an imminent generic launch in the cited record.
- Prevymis should remain commercially durable through the current decade, with patent erosion as the principal long-term risk.
FAQs
Is letermovir more effective than valganciclovir?
Letermovir demonstrated noninferiority to valganciclovir for prevention of CMV disease in high-risk kidney transplant recipients and generally causes less leukopenia or neutropenia. Its clinical value is strongest in patients for whom marrow toxicity is a major concern.
Does letermovir treat active CMV infection?
Prevymis is primarily approved for CMV prophylaxis. It is not the standard product for treating established refractory or resistant CMV disease. Maribavir and other antivirals occupy the treatment setting.
Is Prevymis approved for solid-organ transplants other than kidney?
The major FDA solid-organ indication is high-risk adult kidney transplantation. Use in other solid-organ transplant populations may occur under institutional protocols or off-label practice, but approval and reimbursement depend on the specific indication.
Can a generic letermovir omit the kidney-transplant indication?
A generic applicant may attempt a section viii labeling strategy if the relevant method-of-use claims are listed and legally enforceable. The commercial outcome would depend on the remaining composition and formulation patents and on how physicians prescribe the product.
What would happen to Prevymis revenue after generic entry?
Revenue would likely decline through price discounts, formulary substitution and reduced net pricing. The decline could be slower than for common primary-care drugs because transplant centers value continuity, drug-interaction management and established prophylaxis protocols.
References
-
European Medicines Agency. (2018). Prevymis: EPAR - product information. https://www.ema.europa.eu/
-
Food and Drug Administration. (2017). FDA approves new drug to prevent CMV infection in transplant patients. https://www.fda.gov/
-
Food and Drug Administration. (2023). FDA approves Prevymis for prevention of CMV disease in adult kidney transplant recipients. https://www.fda.gov/
-
Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Limaye, A. P., et al. (2023). Letermovir versus valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients. JAMA, 330(1), 33-44.
-
Marty, F. M., et al. (2017). Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. New England Journal of Medicine, 377(25), 2433-2444.
-
Merck & Co., Inc. (2023). 2022 annual report. https://www.merck.com/investor-relations/financial-information/
-
Merck & Co., Inc. (2024). 2023 annual report. https://www.merck.com/investor-relations/financial-information/
-
Merck & Co., Inc. (2025). 2024 annual report. https://www.merck.com/investor-relations/financial-information/
-
World Intellectual Property Organization. (2006). WO 2006/133822, antiviral compounds. PATENTSCOPE. https://patentscope.wipo.int/
